CARC-101C / Carcell Biopharma - LARVOL DELTA

First-in-Human Evaluation of CARC-101C, an Engineered Red Blood Cell Therapy Delivering an Insulin Autoantigen, in Adults with Autoimmune Type 1 Diabetes (ADA 2026) - "A single low-dose infusion of CARC-101C demonstrated a favorable safety profile with no immune activation in adults with T1D. For some patients with residual β-cell activity, CARC-101 may help slow the decline of islet function. These findings support continued clinical evaluation of eRBC-based autoantigen delivery as a well-tolerated and clinically practical strategy for antigen-specific immune tolerance in T1D."

Clinical • First-in-human • P1 data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P1 trial • Diabetes • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus